AMRX
Amneal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$20.21
−1.13%Price chart
Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3
Key dataNov 3, 2026
Open$19.93
From 52W high−6.04%
Volume6.44M
Market cap$6.45B
P/E (TTM)40.6x
P/S (TTM)2.1x
Div yield—
Key dataNov 3, 2026
Open
$19.93
From 52W high
−6.04%
Volume
6.44M
Market cap
$6.45B
ValuationView details →
P/E (Fwd)
18.6x
EV/EBITDA
14.1x
P/E (TTM)
40.6x
RSI (14)
50.8
MomentumView details →
1D Return
−1.13%
YTD Return
+60.16%
SummaryUpdated Sep 1, 2026
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is a specialty and generic pharmaceutical company founded in 2002 and headquartered in Bridgewater, New Jersey. The company went public in May 2018 following its transformation from Atlas Holdings, Inc. Amneal has evolved from a traditional generic drug manufacturer into a diversified pharmaceutical company with operations spanning generic medicines, specialty branded products, and healthcare distribution services. The company operates manufacturing facilities in the United States, India, and Ireland, serving customers globally through a comprehensive portfolio of pharmaceutical products and services.
Similar companies
Latest newsMore news →
Amneal Pharmaceuticals, Inc. reported quarterly earnings of $0.26 per share, up from $0.17 per share a year earlier.1d agoAmneal reported third-quarter 2026 net revenue of $863 million, a GAAP net loss of $22 million, diluted loss per share of $0.06, adjusted EBITDA of $207 million and adjusted diluted EPS of $0.26.1d agoAmneal Pharmaceuticals announced that it will report its third-quarter 2026 financial results before market open on November 3, 2026, and host an audio webcast at 8:30 a.m. ET.27d ago